Clinical symptoms and cognitive functioning following adjunctive N-acetylcysteine in obsessive-compulsive disorder: a double-blind, placebo-controlled trial
AI Summary
Adjunctive NAC 2400 mg/day with sertraline yielded significantly greater Y-BOCS total reduction over 12 weeks, strongest effect on obsession symptoms.
Clinical response rate ≥35% was higher with NAC (100%) than placebo (92.6%), difference statistically significant.
Both groups improved in processing speed and attention, with no significant between-group cognitive differences; adverse events were mild and comparable.
Commun Med (Lond). 2026 Jun 8. doi: 10.1038/s43856-026-01711-6. Online ahead of print.
ABSTRACT
BACKGROUND: Obsessive-compulsive disorder (OCD) often remains partially responsive to first-line treatments such as selective serotonin reuptake inhibitors (SSRI). N-acetylcysteine (NAC), a glutamate-modulating antioxidant, has shown promise as an adjunctive therapy, but prior studies frequently lacked standardized pharmacotherapy and cognitive outcome measures, particularly in Iranian populations.
METHODS: In this 12-week, double-blind, placebo-controlled randomized clinical trial (IRCT20170123032145N7, registered on 2023-06-08), 35 adults with moderate to severe OCD were assigned to receive sertraline (200 mg/day) augmented with either NAC (2400 mg/day) or placebo. Clinical symptoms were assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline, weeks 4, 8, and 12. Cognitive functioning was evaluated before and after treatment using the Wisconsin Card Sorting Test and the D2 Test of Attention.
RESULTS: This pilot study reveals a significant Time × Group interaction for Y-BOCS Total (p < 0.005), with the NAC group showing greater symptom reduction than placebo. The Obsession subscale demonstrates the strongest effect (p < 0.001), while Compulsion subscale improvements are comparable between groups. Clinical response rate ( ≥ 35% Y-BOCS reduction) is significantly higher in the NAC group (100%) versus placebo (92.6%, p = 0.004). Both groups improve on cognitive measures (processing speed and attention) over time, with no significant between-group differences. Adverse events are mild and comparable.
CONCLUSIONS: Adjunctive NAC may enhance early clinical response in OCD, particularly for obsessions, when added to high-dose SSRI (Sertraline) treatment. However, no cognitive advantage is observed within the 12-week period. These preliminary findings support NAC’s safety and potential utility as a short-term adjunctive treatment in OCD.
Biopsychosoc Sci Med. 2026 Jun 9. doi: 10.1097/PSY.0000000000001498. Online ahead of print.ABSTRACTTo survive and thrive, living organisms must monitor and regulate cell-level energy supply, demand,...
Ann Indian Acad Neurol. 2026 Jun 8. doi: 10.4103/aian.aian_109_26. Online ahead of print.ABSTRACTBACKGROUND AND OBJECTIVES: Wilson's disease (WD) is a systemic copper toxicity disorder, manifesting...
Saudi J Kidney Dis Transpl. 2026 Jun 3. doi: 10.4103/sjkdt.sjkdt_119_22. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease is an important health issue all over the...
JAMA Netw Open. 2026 Jun 1;9(6):e2617336. doi: 10.1001/jamanetworkopen.2026.17336.ABSTRACTIMPORTANCE: Nonsuicidal self-injury (NSSI)-a major threat to adolescents with major depressive disorder (MDD), substantially raising hospitalization and suicidality...
JAMA Netw Open. 2026 Jun 1;9(6):e2617466. doi: 10.1001/jamanetworkopen.2026.17466.ABSTRACTIMPORTANCE: Prostate cancer often requires frequent in-person clinical visits, imposing substantial travel, financial, and time burdens for patients....
J Appl Physiol (1985). 2026 Jun 9. doi: 10.1152/japplphysiol.00667.2025. Online ahead of print.ABSTRACTDuring spaceflight, the lack of gravity-induced hydrostatic pressure gradients in the body results...
